It was a pleasure to speak with Bob Geng (University of California, San Diego, CA, USA) to discuss study results investigating subcutaneous human immunoglobulin 16.5% in patients with primary immunodeficiencies.
The abstract entitled ‘Long-Term Safety, Efficacy, and Tolerability of Subcutaneous Human Immunoglobulin 16.5% in Patients with Primary Immunodeficiencies‘ (ABSTRACT NUMBER: 238) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.
Part 1 of our discussion can be viewed here.
Questions:
1. Could you tell us a little about the study you are presenting and its findings? (0:18)
2. What are the implications of these findings for clinical practice? (2:18)
3. Which patients will benefit most from subcutaneous human IgG 16.5% and in whom should it be avoided? (5:19)
Disclosures: Bob Geng as acted as consultant/speaker for Takeda and Grifols; a consultant for Koru and Kedrion and provided clinical trial support for Octapharma.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAAAI 2021 (Virtual).
